Bone cancer pain (BCP) is one of the most common pains in patients with malignant cancers. The mechanism underlying BCP is largely unknown. Our previous studies and the increasing evidence both have shown that acid-sensing ion channels 3 (ASIC3) is an important protein in the pathological pain state in some pain models. We hypothesized that the expression change of ASIC3 might be one of the factors related to BCP. In this study, we established the BCP model through intrathecally injecting rat mammary gland carcinoma cells (MRMT-1) into the left tibia of Sprague-Dawley female rats, and found that the BCP rats showed bone destruction, increased mechanical pain sensitivities and up-regulated ASIC3 protein expression levels in L4-L6 dorsal root ganglion. Then, resveratrol, which was intraperitoneally injected into the BCP rats on post-operative Day 21, dose-dependently increased the paw withdrawal threshold of BCP rats, reversed the pain behavior, and had an antinociceptive effect on BCP rats. In ASIC3-transfected SH-SY5Y cells, the ASIC3 protein expression levels were regulated by resveratrol in a dose-and time-dependent manner. Meanwhile, resveratrol also had an antinociceptive effect in ASIC3-mediated pain rat model. Furthermore, resveratrol also enhanced the phosphorylation of AMPK, SIRT1, and LC3-II levels in ASIC3-transfected SH-SY5Y cells, indicating that resveratrol could activate the AMPK-SIRT1-autophagy signal pathway in ASIC3-transfected SH-SY5Y cells. In BCP rats, SIRT1 and LC3-II were also down-regulated. These findings provide new evidence for the use of resveratrol as a therapeutic treatment during BCP states.
Introduction
Cancer pain is one of the most common clinical symptoms associated with malignant cancers [1] . Up to 50% of malignant cancers will eventually metastasize to bones, such as the vertebrae, ribs, hip, femur, and tibia. Once tumor cells begin to grow in the bone, a cycle including tumor growth, bone destruction and formation of woven bone will begin, resulting in significant bone pain [2] . These bone cancer pain (BCP) is usually described as dull in character and constant in presentation, while the intensity of pain will gradually increase with time goes by, greatly affecting the quality of the patients' life and their functional states [2, 3] . Until now, the pathological and molecular mechanisms of BCP have not been fully elucidated. The understanding the mechanism of BCP is critical for developing effective strategies for pain management.
Bone cancer induces mechanical bone deformation and local tissue acidosis which may activate acid-sensitive nociceptors via multiple molecular mechanisms, particularly by activation of transient receptor potential vanilloid receptor type 1 (TRPV1) and acidsensing ion channels 3 (ASIC3) [4] . During bone cancer, proton is released, decreasing extracellular pH level (pH 4.0-5.0) and maintaining an acidic pH microenvironment at the osteoclast-mineralize bone interface [5] . The released proton activates ASIC3 expression in both dorsal root ganglion (DRG) cell bodies and sensory terminals, which contributes to proton-evoked pain signaling [6] . Studies have shown that ASICs, rather than TRPV1, mediate pain sensation induced by peripheral proton [7] . Our previous studies and increasing evidence have shown that ASICs play an important role in various pain conditions such as inflammatory pain [8] , post-operative pain [9] , migraine [10] , and BCP [11] [12] [13] . Nevertheless, the mechanisms of ASIC3 in the BCP are still unclear.
Resveratrol (3, 5 ,40-trihydroxystilbene) is a natural polyphenolic flavonoid which exists in both cis and trans isomers in nature. However, the trans isomer is the most abundant and the biologically active form [14] . Resveratrol possesses several effects, such as antioxidant, anticancer, antiproliferative, and potentially analgesic effects [15] . It has been reported that resveratrol has an antinociceptive effect in acute and inflammatory pain models, morphine-tolerant pain models, and BCP models [16] . Resveratrol has multiple targets and SIRT1 is the most frequently studied one among them. SIRT1, an anicotinamide adenosine dinucleotide (NAD+)-dependent deacetylase, is involved in the development of chronic pain [17, 18] . However, the exact working mechanism of resveratrol in BCP has not been clarified.
We hypothesized that altered expression of ASIC3 is related to BCP and maybe also involved in the antinociceptive effect of resveratrol. In this study, we examined the role of resveratrol in rat model of BCP, investigated the expression levels of ASIC3 in L4-L6 DRG of BCP rats, and explored the underlying mechanism.
Materials and Methods

Animals and resveratrol treatment
Animals used for bone cancer model and all experiments were female Sprague-Dawley (SD) rats weighing 160-200 g. All of them were purchased from the Hubei Province Experimental Animal Center (Wuhan, China). All experiments conformed to local and international guidelines on ethical use of animals and all efforts were made to minimize the number of animals used and their sufferings.
Resveratrol (Sigma-Aldrich, St Louis, USA) was first dissolved in dimethyl sulfoxide (DMSO). In animal experiments, resveratrol was diluted with saline to a final DMSO concentration of 10%, and then injected intraperitoneally into BCP rats (0.3, 1, and 3 mg/kg, 100 μl). In cell experiments, resveratrol was diluted with DMSO to different concentrations.
Cell culture and cell transfection
MRMT-1 rat mammary gland carcinoma cells were purchased from JENNIO Biological Techonology (Guangzhou China). Cells were cultured in RPMI 1640 medium (GIBCO, Carlsbad, USA), containing 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, USA), 1% L-glutamine, and 2% penicillin/streptomycin (GIBCO). Cells were released from the plastic by brief exposure to 0.1% (w/v) trypsin, then washed twice and suspended in an appropriate volume of Hank's solution to a final concentration of 4 × 10 6 cells/ml.
Hank's solution was also used for inoculation in control rats.
SH-SY5Y neuroblastoma cells were cultured in DMEM (GIBCO) containing 10% fetal bovine serum (Hyclone), 50 U/ml penicillin and 50 μg/ml streptomycin (GIBCO). Cells were grown in a humidified incubator at 37°C with 5% CO 2 .
Cells were transiently transfected with GFP-ASIC3 (4 μg), eGFP-C1 (4 μg) as a control, mixed GFP-ASIC3/SIRT1 Flag vectors (1 μg/ 3 μg) or GFP-ASIC3/pcDNA3.1 (1 μg/3 μg) as a control respectively, using Lipofectamine ® 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The plasmid pcDNA3.1-SIRT1 Flag was a gift from Prof Verdin E (Department of Physiology, University of California, San Francisco, USA) [19] and GFP-ASIC3 was a gift form Prof Xu T (Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China) [20] . Cells were released from the plastic by brief exposure to 0.1% (w/v) trypsin, then washed twice and collected for western blot analysis [21] .
Rat model of BCP
A rat model of BCP was established following previous reports [22] . In brief, female SD rats were deeply anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg). The left leg of the rat was shaved and the top half of the tibia was carefully exposed after disinfection with 7% iodine and 75% (v/v) ethanol. MRMT-1 cells (10 μl, 4 × 10 6 cells/ml) were slowly injected into the intramedullary space of the left tibia in the BCP rats, whereas an equivalent volume of Hank's solution was injected into the sham rats using a 10 μl Hamilton microsyringe. The syringe was left in the injection site for an additional minute to prevent the leakage of tumor cells. The injection site was sealed with bone wax after the syringe was removed. Then, the wound was closed after being carefully disinfected with 75% (v/v) ethanol. Animals were placed on a warm pad until they had regained consciousness and were returned to their home cages.
Mechanical hyperalgesia
Rats were placed on a 5 × 5-mm wire mesh grid floor and allowed to habituate for 30 min. Testing was blind with respect to group. The von Frey filaments (Stoelting, Wood Dale, USA) ranging from 0.4 to 26 g were used to apply mechanical stimuli to the left hind paw. The 50% paw withdrawal threshold (PWT) was determined by Chaplan's up-down method [23, 24] . In brief, the calibrated monofilaments were applied perpendicularly to the plantar surfaces until the filaments were bent, and a brisk withdrawal was considered as positive response. Whenever a positive response occurred, the von Frey filament with the next lower force was applied, and whenever a negative response occurred, the filament with the next higher force was applied. Then, the pattern of positive and negative withdrawal responses was converted into 50% PWT.
Western blot analysis
Ipsilateral L4-L6 DRG was collected and frozen in lipid nitrogen. Frozen DRG and cells were homogenized in a RIPA lysis buffer containing a cocktail of protease inhibitors (Sigma-Aldrich). After centrifugation at 12,000 g for 15 min, the supernatant was used for western blot analysis. 
Flow cytometry assay
Resveratrol-treated cells were detected by flow cytometry after staining with Annexin V-FITC apoptosis detection kit (Beyotime, Nantong, China) [21] . 
Statistical analysis
Statistical analyses were performed using the Student's t-test or analysis of variance (ANOVA). Values of P < 0.05 were considered to be statistically significant.
Results
Validation of BCP rat models
In this study, we injected female SD rats with intra-tibia MRMT-1 rat mammary gland carcinoma cell to make an animal model for BCP. The BCP rats showed bone destruction and apparently erosion of the cortical bone in the left tibia on the post-operative day (POD) 21 examined by tibia radiographs (Fig. 1A) . Meanwhile, in rats receiving intra-tibia tumor cell injection, mechanical pain sensitivities were significantly increased, beginning on POD 14 (P < 0.05), increasing through POD 17 (P < 0.01), and continuing through POD 24 (last time point examined; P < 0.01) (Fig. 1B) . Nevertheless, no significant changes in bone structure and pain sensitivity were detected in sham-operated rats. In addition, it has been reported that ASIC3 is abundantly expressed in DRG and plays an important role in BCP [13] . Therefore, western blot analyses were performed to quantify the protein expression level of ASIC3 in the ipsilateral L4-L6 DRG of BCP rats. Compared with sham rats, the level of ASIC3 (59 kDa) in L4-L6 DRG in BCP rats was enhanced on POD 21 (P < 0.01; Fig. 1C ). The expression of ASIC3 was elevated by 53% ± 5% in the ipsilateral DRGs, with the relative ASIC3/β-actin ratio in BCP rats vs that in sham rats to be 1.88 ± 0.05 (P < 0.01; Fig. 1C,D) .
Resveratrol reverses pain behavior in BCP rats
To study the role of resveratrol in BCP, we intraperitoneally injected vehicle, or resveratrol (0.3, 1 and 3 mg/kg) into BCP rats on POD 21 and detected the PWT changes. As shown in Fig. 2A , no significant difference was observed between PWT before and after vehicle injection in our time range of investigation. Compared with the vehicle-treated rats, rats treated with 0.3 mg/kg resveratrol resulted in a significant increase in PWT at 0.5 h post injection (PWT vehicle vs PWT 0.3 mg/kg: 4.9 ± 0.9 vs 7.6 ± 1.9, P < 0.05), rats treated with 1 mg/kg of resveratrol resulted in a significant increase in PWT at 0.5 h post injection (PWT vehicle vs PWT 1 mg/kg: 4.9 ± 0.9 vs 8.2 ± 1.0, P < 0.05), 2 h (PWT vehicle vs PWT 1 mg/kg: 6.3 ± 2.1 vs 9.1 ± 1.7, P < 0.05) and 4 h (PWT vehicle vs PWT 1 mg/kg: 5.6 ± 1.5 vs 9.6 ± 1.6, P < 0.05), rats treated with 3 mg/kg of resveratrol resulted in a significant increase in PWT at 0.5 h post injection (PWT vehicle vs PWT 3 mg/kg: 4.9 ± 0.9 vs 12.3 ± 1.5, P < 0.01), 2 h (PWT vehicle vs PWT 3 mg/kg: 6.3 ± 2.1 vs 11.5 ± 1.5, P < 0.01), 4 h (PWT vehicle vs PWT 3 mg/kg: 5.6 ± 1.5 vs 12.7 ± 1.6, P < 0.01) and 6 h (PWT vehicle vs PWT 1 mg/kg: 6.7 ± 2.1 vs 12.5 ± 1.6, P < 0.01). However, 3 mg/kg resveratrol had no effect on the PWT of normal rats (Fig. 2B) .
Resveratrol dose-dependently increased the PWT of BCP rats in our investigated condition, indicating that the resveratrol treatment reversed the pain behavior and had an antinociceptive effect in BCP rats.
Resveratrol regulates the expression levels of ASIC3 and ASIC3-mediated pain
In order to know whether the ASIC3 protein expression level was regulated by resveratrol, SH-SY5Y cells transfected with GFP-ASIC3 were treated with resveratrol. The expression levels of GFP-ASIC3 (79 kDa) were assayed by western blot analysis and the endogenic ASIC3 protein (59 kDa) expression was ignored. As shown 3 mg/kg resveratrol group, green ▲: 1 mg/kg resveratrol group, and blue ▼: 3 mg/kg resveratrol group). All data were expressed as the mean ± SEM, n = 9. (*P < 0.05, **P < 0.01 vs the vehicle group rats at each corresponding time point). (B) PWT of normal rats after intraperitoneal injection of vehicle (DMSO + saline) and 3 mg/kg resveratrol. (□: vehicle group, red •: 3 mg/kg resveratrol group). All data were expressed as the mean ± SEM, n = 9. (C) The flinch/shaking response of rats in the acidosis-evoked pain after intraperitoneal injection of vehicle (DMSO + saline) and 3 mg/kg resveratrol. Flinching shaking of paw was recorded as the number of flinches per observation period (5 min). **P < 0.01, unpaired t-test, compared with control column. n = 9. The results were shown as the mean ± SD. Three independent experiments were performed, *P < 0.05, **P < 0.01.
in Fig. 3A ,B, GFP-ASIC3 protein level in the total lysate and membrane were down-regulated by resveratrol in a dose-dependent manner. The levels of GFP-ASIC3 protein in the total lysate were reduced by 24% (P < 0.05) after treatment with 0.1 μM resveratrol, and 53% (P < 0.01) after treatment with 1 μM resveratrol (Fig. 3D) . The levels of GFP-ASIC3 protein in the membrane were reduced by 45% (P < 0.05) after treatment with 0.1 μM resveratrol, and 80% (P < 0.01) after treatment with 1 μM resveratrol (Fig. 3E) . And the GFP-ASIC3 protein level in total lysis were also down-regulated by resveratrol in a time-dependent manner (Fig. 3C,F) . The levels of GFP-ASIC3 protein were reduced by 23% (P < 0.05) after treatment with 1 μM resveratrol for 12 h, and 50% (P < 0.01) after treatment with 1 μM resveratrol for 24 h (Fig. 3F) .
Further, we examined the effect of resveratrol on the acidosisevoked pain which was potently blocked by amiloride, an ASIC channel blocker [25] . And as shown in Fig. 2C , the number of flinches were decreased from 25 ± 1.5 of control conditions to 13 ± 1.3 with resveratrol pretreatment (n = 9, P < 0.01), suggesting that resveratrol blocked the ASIC3-mediated pain.
These data illustrate that the expression level and function of ASIC3 are regulated by resveratrol, and ASIC3 is involved in the antinociceptive effect of resveratrol in BCP rats.
Resveratrol activates autophagy signal pathway
Our data demonstrated that resveratrol treatment reversed the pain behavior in BCP rats and regulated the expression level and function of ASIC3. To investigate the underlying mechanism, we examined the protein expression level of autophagy-related proteins in animal model and cell culture.
First, in ASIC3-transfected SH-SY5Y cells treated with DMSO or 1 μM resveratrol, the protein expression level of autophagy marker LC3-II (a late light chain 3 autophagosome marker) was detected. It was found that the protein level of LC3-II was increased in the resveratrol-treated cells (Fig. 4A) , compared with that in the DMSO-treated cells. Then the protein signal of AMPK pathway was clarified in DMSO and resveratrol-treated cells. Compared with the DMSO-treated cells, the protein levels of phosphorylated AMPK on Thr172 were also increased in the resveratrol-treated cells. Additionally, the protein levels of SIRT1 got a significant increase with resveratrol treatment, which was consistent with the change of p-AMPK and LC3-II. Meanwhile, to determine cell apoptosis induced by resveratrol treatment in ASIC3-transfected SH-SY5Y cells, we performed Annexin V-FITC and PI double straining followed by flow cytometry. As shown in Fig. 4B ,C, the percentages of early apoptotic cells and late apoptotic or necrotic cells in ASIC3-transfected SH-SY5Y cells treated with 1 μM resveratrol for 24 h were 2.05% and 0.26%, respectively, which were not remarkably different from those in ASIC3-transfected SH-SY5Y cells treated with DMSO (2.00% and 0.19%).
Moreover, in BCP rats on POD 21, it was found that SIRT1 and LC3-II protein levels were down-regulated in the L4-L6 DRG (Fig. 4D) , indicating that autophagy signal pathway was downregulated in BCP rats.
Based on these data, we supposed that SIRT1, as a target of resveratrol, could regulate ASIC3 protein expression. Western blot analysis was performed to quantify the expression level of ASIC3 protein in SH-SY5Y cells co-transfected with ASIC3/SIRT1. As shown in Fig. 4E , the over-expression of SIRT1 resulted in a significant decrease of ASIC3 protein level in ASIC3-transfected SH-SY5Y cells. These data indicated that resveratrol activated the AMPK-SIRT1-autophagy signal pathway in ASIC3-transfected SH-SY5Y cells.
Discussion
In the present study, we demonstrated that resveratrol could reverse pain behavior in BCP rats. Resveratrol also regulated the expression level of ASIC3 and ASIC3-mediated pain behavior by activating the cell autophagy.
BCP, which strongly affects the patient's quality of life, is unique compared with other chronic pain. Until now, the treatment of BCP remains one of the most challenging cancer pains to be fully controlled. Safe and applicable treatments for BCP are urgently needed. Resveratrol, as a natural polyphenolic flavonoid, had been shown to be beneficial to health and capable of resulting in various biological actions. It has been well documented that resveratrol has therapeutic potential in a wide variety of chronic ailments including cancer, cardiovascular diseases, skin disorders, diabetes, neurological diseases, arthritis, and even the aging process [26] . Furthermore, resveratrol has been shown to have antinociceptive effects in BCP [27] . In the present study, we also found that intraperitoneal injection of 0.3, 1, and 3 mg/kg resveratrol had a significant antinociceptive effect on BCP rats. Compared with the vehicle group, 0.3 mg/kg resveratrol had an antinociceptive effect at 0.5 h post injection, and the effects decreased at 2 h post injection. Meanwhile, these antinociceptive effects lasted for 4 h in the 1 mg/kg resveratrol group, and at least 6 h in the 3 mg/kg resveratrol group. These data indicated that, considering the metabolism of resveratrol, the working concentration of resveratrol should be at least 0.3 mg/kg for intraperitoneal injection.
Until now, the exact working mechanism of resveratrol in BCP rats still remains unclear. It was reported that resveratrol could decrease the expression and glial activation of CX3C chemokine receptor 1 in the spine of BCP rats [27] . And we found that resveratrol could regulate the expression level of ASIC3, which was upregulated in L4-L6 DRG of the BCP rats. Compelling evidence in the literature has shown that resveratrol is capable of inducing autophagy in different cancer cell line models [28] and in neuronal cells [29] . In this study, we showed that in ASIC3-transfected SH-SY5Y cells treated with resveratrol, the basal level of LC3 was decreased, while the level of LC3-II was increased, indicating that resveratrol activates autophagy. Extensive studies have indicated that autophagy plays important neuroprotective roles in many neuron-diseases [29] [30] [31] . However, it was also reported that resveratrol could induce autophagy and activate cell apoptosis in several cancer cell lines [15, 32] . Therefore, we performed doublestaining using Annexin V-FITC and PI to detect the effect of resveratrol on the ASIC3-transfected SH-SY5Y cell apoptosis. And as shown in Fig. 4B ,C, the addition of resveratrol did not induce apoptosis of the ASIC3-transfected SH-SY5Y cell under our investigation condition.
The regulation of autophagy by resveratrol may be through various pathways. We found that there was an increase of p-AMPK level in the ASIC3-transfected SH-SY5Y cells treated with resveratrol, accompanied with the increased protein level of LC3-II. Activation of AMPK causes the increase of cellular SIRT1 activity [33] , while SIRT1 plays an important role in the regulation of pathogenesis of chronic disease [34] . In the current study, we found that SIRT1 protein level was down-regulated in the L4-L6 DRG of BCP rats, and resveratrol could increase SIRT1 expression level. Our results provide evidence that resveratrol may active the AMPK/ SIRT1 pathway, which is required for the autophagy induction.
Based on our own data, we propose a valuable hypothetical model showing how resveratrol attenuates BCP (Fig. 5) . In bone cancer model rats, the cancer cells activate ASIC3, and ASIC3 provokes pain signaling. When rats are treated with resveratrol, resveratrol activates AMPK-SIRT1-autophagy signal pathway and decreases the expression level of ASIC3, resulting in an antinociceptive effect. 
